December 11, 2020
XNK Therapeutics AB (“XNK”) announces its collaboration agreement with Israel-based Cellect Biotechnology (“Cellect”) to develop the next generation version of XNK’s innovative technology platform.
Under the terms of the agreement, Cellect will work to further improve XNK Therapeutics’ technology platform for targeting cancer across a wide range of indications. Cellect’s functional cell selection technology has the potential to significantly improve the consistency and manufacturing efficiency in autologous cell therapies.
“I am excited that we will be able to continue developing the next generation of XNK Therapeutics’ technology platform in collaboration with Cellect,” said Johan Liwing, CEO of XNK Therapeutics.
“We recognize the growing interest in NK cells and decided to work with XNK Therapeutics for further dissemination of our Apograft technology,” said Dr. Shai Yarkoni, CEO of Cellect Biotechnology.
For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden.
For more info, please visit www.xnktherapeutics.com
About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen. The assets of XNK Therapeutics are protected by patents in the US, Europe and certain other jurisdictions. Additional patent applications have been filed.
About XNK Therapeutics’ therapy
The leading drug candidate from XNK Therapeutics’ technology platform was previously clinically tested in a first-in-human Phase I/II clinical trial (ACP-001). The study was performed at the Karolinska University Hospital, Stockholm, Sweden, in a setting of consolidation treatment following high dose stem cell transplantation in patients newly diagnosed with multiple myeloma. The study was an open, single-arm, triple escalating dose/patient clinical trial with the primary objective of studying the product’s safety and tolerability. In the study, the therapy showed a very good safety profile, and promising efficacy data. XNK Therapeutics is continuing its clinical development in multiple myeloma and plans to initiate a Phase II clinical trial in the near future.